Lapeere H, Baeck M, Stockman A, et al. - In adults with chronic spontaneous urticaria (CSU), characterized by the repeated occurrence of persistent hives and/or angioedema for ≥ 6 weeks, without specific external stimuli, in Belgium, researchers gathered real-world clinical information on omalizumab therapy. The study sample consisted of adults with CSU (n = 235), who started omalizumab treatment between August 2014 and December 2016 (maximum 28 months follow-up). According to this observational, retrospective chart review, patients started on omalizumab in Belgium had severe CSU at baseline, and exhibited substantial improvements after 1 month of treatment and continued benefit for up to 28 months of treatment with omalizumab. Before starting and in combination with omalizumab in Belgium, findings also identified a need for greater adherence to the prescription of guideline-recommended medication. The most common adverse event was a headache. There was no reported anaphylaxis.